Anti-ENTPD1 Antibody

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1), widely known as CD39, is a membrane-bound ectoenzyme that hydrolyzes extracellular ATP and ADP to AMP, acting as a central gatekeeper of purinergic signaling in immune and vascular tissues. This unconjugated rabbit polyclonal reagent supplied by Antibodies.com is raised against the full-length human ENTPD1 sequence and validated for western blot (WB) and immunohistochemistry (IHC) workflows.

CD39 is strongly expressed on endothelial cells, B lymphocytes, and subsets of regulatory T cells, where its ATPase activity shapes the immunosuppressive tumor microenvironment by depleting pro-inflammatory extracellular nucleotides and feeding the adenosine pathway. Investigators working in cancer immunology, transplant tolerance, vascular biology, and chronic inflammation rely on anti-CD39 reagents to map tissue expression, characterize tumor-infiltrating lymphocyte subsets, and interrogate the CD39/adenosine axis as a therapeutic checkpoint.

The antibody cross-reacts with the mouse and rat orthologs, supporting comparative work in syngeneic and xenograft preclinical models. Each vial contains 100 µl of unconjugated polyclonal antiserum in a liquid format ready for standard immunostaining and immunoblotting protocols. For best results, refrigerate short-term, aliquot upon first thaw, and limit freeze-thaw cycles to preserve performance across multiple staining runs.